Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;5(5 Suppl 2):S131-3.
doi: 10.5489/cuaj.11182.

Drugs and future candidates

Karl-Erik Andersson  1
Affiliations

Drugs and future candidates

Karl-Erik Andersson. Can Urol Assoc J. 2011 Oct.

Abstract

Antimuscarinic drugs are still first-line treatment for the symptoms of overactive bladder (OAB) and are associated with good initial response rates. Adverse effects and decreasing efficacy over the longer term do, however, limit their overall effectiveness. As such, alternatives to antimuscarinics are needed. The recognition of the functional contribution of the urothelium, the spontaneous myocyte activity during bladder filling, and the diversity of nerve transmitters involved in the symptoms of the OAB has sparked interest in pharmacologic manipulation of both peripheral and central pathophysiology. Some of the treatments currently under investigation are discussed in this review.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
ß3-Adrenoceptor (AR) agonist vs. placebo: reduction in urgency episodes/24-hr. Chapple et al.
See this image and copyright information in PMC

References

    1. Kuo HC, Liu HT, Chancellor MB. Can urinary nerve growth factor be a biomarker for overactive bladder? Rev Urol. 2010;12:e69–77. - PMC - PubMed
    1. Liu H-T, Wang Y-S, Chancellor M, et al. Nerve growth factor levels in urine correlate with expression in urothelium but not suburothelium in the bladder tissues of overactive bladder syndrome [abstract] J Urol. 2010;183(4 Suppl):e644–5.
    1. Bschleipfer T, Schukowski K, Weidner W, et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci. 2007;80:2303–7. - PubMed
    1. Mukerji G, Yiangou Y, Grogono J, et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 2006;176:367–73. - PubMed
    1. De Laet K, De Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn. 2006;25:156–61. - PubMed